Author

S. Kubicek

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Assay:proteomics· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1

Frequent Co-Authors

A. Ringler· 3 shared C. Bock· 3 shared A. Rendeiro· 2 shared B. Wingelhofer· 2 shared K. L. Bennett· 2 shared K. Parapatics· 2 shared P. Majek· 2 shared R. Moriggl· 2 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Ringler

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

DNMT3A harboring leukemia-associated mutations directs sensitivity to DNA damage at replication forks

K. Venugopal, P. Nowialis, Y. Feng, D. E. Shabashvili, C. M. Berntsen, K. I. Krajcik, C. Taragjini, Z. Zaroogian, H. L. Casellas-Roman, L. M. Posada, C. Gunaratne, J. Li, D. Dupere-Richer, R. L. Bennett, S. Pondugula, , O. A. Guryanova

This study shows that DNMT3A mutations impair replication fork recovery, leading to DNA damage and sensitivity to nucleoside analogs like cytarabine.

bioRxiv · May 28, 2021Cancer Biology

STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pigmentation pathway

A. Swoboda, R. Soukup, K. Kinslechner, B. Wingelhofer, D. Schoerghofer, C. Sternberg, H. Pham, M. Vallianou, J. Horvath, D. Stoiber, L. Kenner, L. Larue, V. Poli, F. Beermann, T. Yokota, , R. Moriggl

This study shows that STAT3 promotes melanoma metastasis by repressing the MITF pigmentation pathway through CEBP induction.

Oncogene · Dec 15, 2020Peer-reviewedCancer Biology

A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs

E. Girardi, A. Cesar-Razquin, K. Papakostas, S. Lindinger, J. Konecka, J. Hemmerich, S. Kickinger, F. Kartnig, A. Ingles-Prieto, G. Fiume, A. Ringler, C.-H. Lardeau, R. K. Kandasamy, S. Kubicek, G. F. Ecker, G. Superti-Furga

This study identifies SLC transporters critical for drug resistance using CRISPR screens in human cells, revealing widespread roles of SLCs in drug uptake and activity.

bioRxiv · Aug 8, 2019Cell Biology

MTHFD1 is a genetic interactor of BRD4 and links folate metabolism to transcriptional regulation

S. Sdelci, A. Rendeiro, P. Rathert, G. Hofstaetter, A. Ringler, H. P. Moll, W. You, K. Klavins, B. Guertl, M. Farlik, S. Schick, F. Klepsch, M. Oldach, P. Buphamalai, F. Schischlik, , S. Kubicek

This study identifies MTHFD1 as a genetic and physical interactor of BRD4, linking folate metabolism to transcriptional regulation and showing synergistic effects on cancer cell viability.

bioRxiv · Oct 10, 2018Cancer Biology

The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

L. Kosack, B. Wingelhofer, A. Popa, B. Vilagos, A. Orlova, P. Majek, K. Parapatics, A. Lercher, B. Agerer, A. Ringler, J. Klughammer, M. Smyth, K. Khamina, H. Baazim, D. A. Rosa, , A. Bergthaler

This study identifies the ERBB-STAT3 axis as a driver of Tasmanian devil facial tumor disease and proposes a dual chemo-immunotherapeutic strategy.

bioRxiv · Apr 12, 2018Cancer Biology